SRP 1007
Alternative Names: SRP-1007Latest Information Update: 20 Mar 2026
At a glance
- Originator Sarepta Therapeutics
- Class Drug conjugates; Immunoconjugates; Immunoglobulin fragments; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spinocerebellar ataxias